Significance of angiotensin 1–7 coupling with MAS1 receptor and other GPCRs to the renin‐angiotensin system: IUPHAR Review 22
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Angiotensins are a group of hormonal peptides and include angiotensin II and angiotensin 1–7 produced by the renin angiotensin system. The biology, pharmacology and biochemistry of the receptors for angiotensins were extensively reviewed recently. In the review, the receptor nomenclature committee was not emphatic on designating MAS1 as the angiotensin 1–7 receptor on the basis of lack of classical G protein signalling and desensitization in response to angiotensin 1–7, as well as a lack of consensus on confirmatory ligand pharmacological analyses. A review of recent publications (2013–2016) on the rapidly progressing research on angiotensin 1–7 revealed that MAS1 and two additional receptors can function as ‘angiotensin 1–7 receptors’, and this deserves further consideration. In this review we have summarized the information on angiotensin 1–7 receptors and their crosstalk with classical angiotensin II receptors in the context of the functions of the renin angiotensin system. It was concluded that the receptors for angiotensin II and angiotensin 1–7 make up a sophisticated cross‐regulated signalling network that modulates the endogenous protective and pathogenic facets of the renin angiotensin system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
New approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276 · cited 2×
“…discuss new research elucidating the role of ACE1 and ACE2 in haemodialysis patients, which may aid the development of targeted therapies that slow the progression of chronic kidney and cardiovascular diseases (Carey, 2015; Malik and Raizada, 2015; Oparil and Schmieder, 2015; Te Riet et al., 2015).”
BackgroundCisternas, F., Morales, M. G., Meneses, C., Simon, F., Brandan, E., Abrigo, J., Vazquez, Y., & Cabello-Verrugio, C. (2015) · Clinical Science · doi:10.1042/cs20140215 · Cited by 83 · cited 2×
“…production of TGF-β1 and collagen in cardiac fibroblasts (Meng et al., 2014; Tao et al., 2014; Zheng et al., 2015a), muscle atrophy of gastrocnemius (Cisternas et al., 2014), pancreatic cell damage (Wang et al., 2014), ICAM-1, VCAM-1, and MCP-1 expression in HUVECs (Liang et al., 2015a,b) is…”
BackgroundAngiotensin-(1-7) attenuates disuse skeletal muscle atrophy via the Mas receptor
Morales, M. G., Abrigo, J., Acuña, M. J., Santos, R. A., Bader, M., Brandan, E., Simon, F., Olguin, H., Cabrera, D., & Cabello-Verrugio, C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.023390 · Cited by 77
Sahara, M., Ikutomi, M., Morita, T., Minami, Y., Nakajima, T., Hirata, Y., Nagai, R., & Sata, M. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvt245 · Cited by 74 · cited 1×
“Several independent reports suggest that deletion of ACE2 leads to vascular diseases (Thomas et al., 2010; Thatcher et al., 2011; Sahara et al., 2013; Rabelo et al., 2016).”
BackgroundMorales, M. G., Olguín, H., Di Capua, G., Brandan, E., Simon, F., & Cabello-Verrugio, C. (2015) · Clinical Science · doi:10.1042/cs20140840 · Cited by 62 · cited 1×
“These effects were reversed by the MAS1 receptor antagonist A-779 (Cabello-Verrugio et al., 2015; Morales et al., 2015).”
BackgroundAtypical signaling and functional desensitization response of MAS receptor to peptide ligands
Tirupula, K. C., Desnoyer, R., Speth, R. C., & Karnik, S. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103520 · Cited by 47 · cited 23×
“However, independent laboratories have reported a lack of MAS1 receptor signalling in response to Ang(1–7) and a lack of evidence for direct Ang(1–7) binding to theMAS1 receptor (Bikkavilli et al., 2006; Shemesh et al., 2008; Zhang et al., 2011; Tirupula et al., 2014a).”
BackgroundResultInfluentialSelf-citation
Cited by
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Devaux, C. A., Rolain, J.-M., & Raoult, D. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.04.015 · Cited by 476
Arendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
How ACE inhibitors transformed the renin–angiotensin system
Bakhle, Y. S. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15045 · Cited by 41
Devaux, C. A., & Camoin-Jau, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042200 · Cited by 20
“Resulting from the cleavage of Ang II by the mACE2 protease, Ang-(1–7) exhibits vasodilatory, anti-proliferative, antiinflammatory, and antifibrotic effects via the G protein-coupled receptor (GPGR) known as Mas 1 (Santos et al., 2003, 2018; Simoes e Silva et al., 2013; Patel et al., 2016; Karnik et al., 2017; Bader e…”
Background
Metadata
- Authors
- Karnik, S. S., Singh, K. D., Tirupula, K., & Unal, H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-03-09
- Volume
- 174
- Issue
- 9
- Pages
- 737-753
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2588448590
- Cited by
- 105
- References
- 7
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.